Article
Institutional implementation of clinical tumor profiling on an unselected cancer population.
JCI insight - 17 Nov 2016
Sholl Lynette M, Do Khanh, Shivdasani Priyanka, Cerami Ethan, Dubuc Adrian M, Kuo Frank C, Garcia Elizabeth P, Jia Yonghui, Davineni Phani, Abo Ryan P, Pugh Trevor J, van Hummelen Paul, Thorner Aaron R, Ducar Matthew, Berger Alice H, Nishino Mizuki, Janeway Katherine A, Church Alanna, Harris Marian, Ritterhouse Lauren L, Campbell Joshua D, Rojas-Rudilla Vanesa, Ligon Azra H, Ramkissoon Shakti, Cleary James M, Matulonis Ursula, Oxnard Geoffrey R, Chao Richard, Tassell Vanessa, Christensen James, Hahn William C, Kantoff Philip W, Kwiatkowski David J, Johnson Bruce E, Meyerson Matthew, Garraway Levi A, Shapiro Geoffrey I, Rollins Barrett J, Lindeman Neal I, MacConaill Laura E
Abstract excerpt
BACKGROUND. Comprehensive genomic profiling of a patient's cancer can be used to diagnose, monitor, and recommend treatment. Clinical implementation of tumor profiling in an enterprise-wide, unselected cancer patient population has yet to be reported. METHODS. We deployed a hybrid-capture and massively parallel sequencing assay (OncoPanel) for all adult and pediatric patients at our combined cancer centers....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.